Wilmington, Delaware, United States · Est. 2001 · 3,200 employees
Incyte is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule and biologic drugs in oncology and inflammation.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
By Phase
18 drugs in development
By Therapeutic Area
top 6
R&D Momentum
76/100
Pipeline Velocity
48/100
Trial Completion Rate
64/100
Pipeline Concentration
45/100
Pipeline Freshness
74/100
Strategic Signals
Activity
Last 14 days
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A Phase 1, Single Dose, Open-Label, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Details
Company Overview
$16.0B
Mkt Cap
$3.5B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI
Application NDA202192
Pemazyre — PEMAZYRE
Application NDA213736 (NDA)
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI
Application NDA202192
Jakafi — OPZELURA
Application NDA215309 (NDA)
Opzelura — OPZELURA
Application NDA215309 (NDA)
tafasitamab — MONJUVI
Application BLA761163
Pemazyre — PEMAZYRE
Application NDA213736
Jakafi — JAKAFI
Application NDA202192
Pemazyre — PEMAZYRE
Application NDA213736
Jakafi — JAKAFI
Application NDA202192
tafasitamab — MONJUVI
Application BLA761163
Jakafi — JAKAFI
Application NDA202192
Jakafi — JAKAFI XR
Application NDA217180 (NDA)
Jakafi — JAKAFI XR
Application NDA217180
Opzelura — JAKAFI XR
Application NDA217180 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)